Bibliography
Found 33 results
Filters: Keyword is CD4 Lymphocyte Count [Clear All Filters]
Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. J Neurovirol. 2013 ;19(2):150-6.
Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014 ;82(23):2055-62.
Better executive function is independently associated with full HIV suppression during combination therapy. AIDS. 2019 ;33(15):2309-2316.
. Brain and liver pathology, amyloid deposition, and interferon responses among older HIV-positive patients in the late HAART era. BMC Infect Dis. 2017 ;17(1):151.
. . CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011 ;25(14):1747-51.
Changes in PINCH levels in the CSF of HIV+ individuals correlate with hpTau and CD4 count. J Neurovirol. 2014 ;20(4):371-9.
. Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol. 2011 ;17(3):248-57.
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol. 2010 ;67(5):552-8.
Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study. Lancet HIV. 2019 ;6(7):e456-e462.
Crack cocaine: effect modifier of RNA viral load and CD4 count in HIV infected African American women. Frontiers in Bioscience: A Journal and Virtual Library [Internet]. 2007 ;12:1488-95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17127396
. Effects of human immunodeficiency virus and methamphetamine on cerebral metabolites measured with magnetic resonance spectroscopy. Journal of Neurovirology [Internet]. 2007 ;13:150-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17505983
. Factors related to HIV-associated neurocognitive impairment differ with age. J Neurovirol. 2015 ;21(1):56-65.
. Family history of dementia predicts worse neuropsychological functioning among HIV-infected persons. J Neuropsychiatry Clin Neurosci. 2011 ;23(3):316-23.
Frontline Science: CXCR7 mediates CD14CD16 monocyte transmigration across the blood brain barrier: a potential therapeutic target for NeuroAIDS. J Leukoc Biol. 2017 ;102(5):1173-1185.
. Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain: A Journal of Neurology [Internet]. 2006 ;129:1872-83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16735456
Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. J Neurovirol. 2012 ;18(2):81-90.
HIV-Associated Cardiovascular Disease: Role of Connexin 43. Am J Pathol. 2017 ;187(9):1960-1970.
. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol. 2008 ;64(5):566-72.
Impact of Antiretroviral Regimens on Cerebrospinal Fluid Viral Escape in a Prospective Multicohort Study of Antiretroviral Therapy-Experienced Human Immunodeficiency Virus-1-Infected Adults in the United States. Clin Infect Dis. 2018 ;67(8):1182-1190.
. Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients. Annals of Neurology [Internet]. 2007 ;62:34-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17328067
. Lithium improves HIV-associated neurocognitive impairment. AIDS (London, England) [Internet]. 2006 ;20:1885-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16954730
. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neurovirol. 2016 ;22(2):170-8.
Low atazanavir concentrations in cerebrospinal fluid. AIDS. 2009 ;23(1):83-7.
Older age and plasma viral load in HIV-1 infection. AIDS. 2004 ;18 Suppl 1:S87-98.